Pentagamavunon-1 Enhances the Anticancer Effects of Doxorubicin on Triple-Negative Breast Cancer Cells in Monolayers and 3D Cancer Spheroid Models

Rahmawati, Desty Restia and Murwanti, Retno and Jenie, Riris Istighfari and Nurrochmad, Arief (2025) Pentagamavunon-1 Enhances the Anticancer Effects of Doxorubicin on Triple-Negative Breast Cancer Cells in Monolayers and 3D Cancer Spheroid Models. Indonesian Biomedical Journal, 17 (3). 241 - 251. ISSN 20853297

[thumbnail of 3587-9815-1-PB.pdf] Text
3587-9815-1-PB.pdf - Published Version
Restricted to Registered users only

Download (1MB) | Request a copy

Abstract

BACKGROUND: The 4T1 cells, a triple-negative breast cancer (TNBC) cell line, exhibit high malignancy and metastatic potential. As a primary treatment for TNBC, doxorubicin has limitations, including drug resistance mechanisms and severe side effects such as cardiotoxicity. Pentagamavunone-1 (PGV-1) exhibits antiproliferative and antimetastatic effects, induces prometaphase arrest, triggers cell senescence, and enhances reactive oxygen species (ROS) modulation, which may help overcome doxorubicin resistance. The selective cytotoxicity of PGV-1 against cancer cells suggests that it has a role in reducing systemic toxicity. Therefore, in this study, the anticancer effects of doxorubicin combined with PGV-1 was investigated. METHODS: Monolayer/2D and spheroid/3D models of 4T1 cells were used to assess the effects of PGV-1, doxorubicin, and their combination. MTT assay was used to evaluate the cytotoxicity, colony formation assay was used to measure persistent antiproliferative effects, and spheroid volume analysis was performed to assessed tumor growth inhibition. Senescence-associated beta-galactosidase (SA-β-gal) assay determined cellular senescence. RESULTS: The combination of PGV-1 and doxorubicin significantly enhanced cytotoxicity, with IC50 values of 0.57 µM and 4.88 µM, respectively (p=0.000). A strong synergistic effect was observed, leading to persistent suppression of cancer cell proliferation and an 80 reduction in colony formation (p=0.007). In the 3D spheroid model, combination treatment significantly reduced spheroid volume (p=0.002) more effectively than monotherapy, indicating superior growth inhibition and cytotoxicity. It also increased SA-β-gal, the senescence marker (p=0.010). CONCLUSION: The combination of PGV-1 and doxorubicin demonstrated potent anticancer effects in 4T1 monolayers and spheroid models by enhancing cytotoxicity and inducing cellular senescence. This combination confirmed its potential as a more effective therapeutic strategy. Copyright © 2025 The Prodia Education and Research Institute. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC-BY-NC) License.

Item Type: Article
Additional Information: Cited by: 1; All Open Access; Gold Open Access; Green Open Access
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy
Depositing User: Muh Aly Mubarok
Date Deposited: 22 Oct 2026 03:13
Last Modified: 22 Oct 2026 03:13
URI: https://ir.lib.ugm.ac.id/id/eprint/30291

Actions (login required)

View Item
View Item